CTOs on the Move

Nevakar

www.nevakar.com

 
Nevakar is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.nevakar.com
  • 1019 US Highway 202-206 Building K
    Bridgewater, NJ USA 08807
  • Phone: 908.367.7400

Executives

Name Title Contact Details

Funding

Nevakar raised $55M on 07/28/2016
Nevakar raised $30M on 11/30/2018

Similar Companies

Network Pharmaceuticals Inc

Network Pharmaceuticals Inc is a Redlands, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision Life Sciences

RESULTS ARE IN OUR DNA Fostering partnerships within the Life Science industry to enable innovation and positive outcomes. CLIENTS JOB SEEKERS Company We Are Precision Life Sciences Precision Life Sciences, a WBE (Woman-Owned Business Enterprise), was ...

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

Bioniche Pharma

Bioniche Pharma is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.